Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 24NET 17Gastrointestinal 8Tumor-Agnostic 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Peritoneal Neoplasms 1Intestinal Obstruction 1Carcinoma 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
lanreotide × Gynecologic × Clear all
NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Ipsen

Phase 3 Completed
80 enrolled
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡